ACCESS Newswire
06 Jul 2022, 16:39 GMT+10
VANCOUVER, BC / ACCESSWIRE / July 6, 2022 / Clairvoyant Therapeutics, a Canadian biotech company, is pleased to announce it has initiated the first of 15 planned sites for CLARITY, the company's Phase 2 clinical trial investigating psilocybin in the treatment of alcohol use disorder (AUD) (formerly called alcoholism).
CLARITY is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of 25 mg synthetic psilocybin in conjunction with Motivational Enhancement Therapy (MET). CLARITY has been approved in Canada and has been submitted for regulatory approval in the EU countries selected for its Phase 2 clinical trial.
'We are delighted to initiate our Phase 2 clinical trial,' said Damian Kettlewell, co-founder and CEO of Clairvoyant. 'At Clairvoyant, it is our hope that the results of this clinical trial will support the company's novel psychedelic treatment model for addressing the significant unmet medical need for AUD patients.'
The remainder of the 15 sites are each in an advanced stage of negotiation. These sites are located in major centres in Canada and Europe. The large number of sites for a psychedelic trial reflects Clairvoyant's objective to be the first company globally to register psilocybin as a therapeutic product to treat AUD patients.
About Alcohol Use Disorder
According to the World Health Organization, 283 million people aged 15 years and older are at risk of alcohol use disorder.[i] Globally, mortality from alcohol consumption is higher than from diseases such as tuberculosis, HIV/AIDS and diabetes.[i]
About Psilocybin Therapy and CLARITY
Psilocybin is the pharmaceutical agent in certain mushrooms which is known to induce a temporary psychedelic state. It was first purified in the 1950s. After thousands of recorded administrations, no addiction or abuse potential has been identified for psilocybin. In the CLARITY trial, subjects are accompanied on their psychedelic treatment journey by two highly trained therapists who have been certified under Clairvoyant's professional and ethical certification program.
About Clairvoyant
Clairvoyant Therapeutics is a Canadian biotechnology company changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.
The company's exceptional team, with a proven clinical track record and deep drug development experience, has made Clairvoyant the most advanced company globally developing psilocybin therapy for the treatment of AUD.
Clairvoyant is committed to meeting the highest standards of verified social and environmental performance, public transparency and legal accountability to balance profit and purpose and is a pending B Corporation Certification. Clairvoyant is a member of Life Science BC and Biotechnology Innovation Organization (BIO).
Learn more at www.clairvoyantrx.com and follow the Company on LinkedIn and Twitter.
-30-
For more information:
Media requests:
Marlo Taylor
[email protected]
Corporate contact:
Damian Kettlewell
[email protected]
[i] World Health Organization. Global alcohol action plan 2022-2030 to strengthen implementation of the Global Strategy to Reduce the Harmful Use of Alcohol First draft. June 2021
SOURCE: Clairvoyant Therapeutics
Get a daily dose of Tennessee Daily news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Tennessee Daily.
More InformationTAIPEI, Taiwan: Taiwan's exports grew much more than expected in April, as buyers rushed to purchase its high-tech products before...
NEW YORK, New York - A better-than-expected CPI reading sent the Standard and Poor's 500 and the Nasdaq Composite higher on Tuesday,...
MONTREAL, Canada: Air Canada has cut its annual core profit forecast and missed first-quarter revenue estimates, citing a drop in U.S.-bound...
CUPERTINO, California: Apple's plan to introduce AI-powered search options on its Safari browser poses a major challenge to Google,...
FRANKFURT, Germany: Foreign workers have emerged as a critical force behind the euro zone's economic growth since the pandemic, offsetting...
NEW YORK, New York - U.S. stocks surged on Monday following news that the Trump administration had agreed to a 90-day reduction of...
TAIPEI, Taiwan: Taiwan's exports grew much more than expected in April, as buyers rushed to purchase its high-tech products before...
REDMOND, Washington: Microsoft has prohibited its employees from using Deepseek, a Chinese artificial intelligence app, citing concerns...
MONTREAL, Canada: Air Canada has cut its annual core profit forecast and missed first-quarter revenue estimates, citing a drop in U.S.-bound...
DUBLIN, Ireland: Ireland recorded its hottest-ever April day as temperatures hit 25.9 degrees Celsius, according to the EU's Copernicus...
CUPERTINO, California: Apple's plan to introduce AI-powered search options on its Safari browser poses a major challenge to Google,...
NEW YORK CITY, New York: Citigroup must defend itself against a revived lawsuit accusing the bank of facilitating and concealing a...